Innate Pharma (IPHA) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.74
• Market Cap: $163.08M
• EPS: $-0.65
• 52-Week High: $2.63
• 52-Week Low: $1.57

Market Sentiment

Innate Pharma currently has a Neutral sentiment score of 0.07.

About Innate Pharma

Innate Pharma SA is a pioneering biotechnology firm headquartered in Marseille, France, specializing in the development of groundbreaking therapeutic antibodies for oncological applications. The company boasts a diverse pipeline of proprietary immune-oncology candidates designed to improve treatment outcomes for cancer patients worldwide. With its strong focus on monoclonal antibody and immune-mediated therapies, Innate Pharma is well-positioned to capitalize on the increasing global demand f...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Innate Pharma and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does IPHA pay dividends?

Innate Pharma (IPHA) does not currently pay a regular dividend.

What is IPHA's market cap?

Innate Pharma (IPHA) has a market capitalization of $163.08M with a current stock price of $1.74.